N. Grobe et al. / FEBS Letters 586 (2012) 1749–1753
1753
[7] Mikus, G., Somogyi, A.A., Bochner, F. and Eichelbaum, M. (1991) Codeine O-
demethylation: rat strain differences and the effects of inhibitors. Biochem.
Pharmacol. 41, 757–762.
[8] Grobe, N., Zhang, B., Fisinger, U., Kutchan, T.M., Zenk, M.H. and Guengerich, F.P.
(2009) Mammalian cytochrome P450 enzymes catalyze the phenol-coupling
step in endogenous morphine biosynthesis. J. Biol. Chem. 284, 24425–24431.
[9] Yamamoto, Y., Tasaki, T., Nakamura, A., Iwata, H., Kazusaka, A., Gonzalez, F.J.
and Fujita, S. (1998) Molecular basis of the Dark Agouti rat drug oxidation
polymorphism: importance of CYP2D1 and CYP2D2. Pharmacogenetics 8,
73–82.
[10] Hiroi, T., Chow, T., Imaoka, S. and Funae, Y. (2002) Catalytic specificity of
CYP2D isoforms in rat and human. Drug Metab Dispos. 30, 970–976.
[11] Bromek, E., Haduch, A. and Daniel, W.A. (2010) The ability of cytochrome P450
2D isoforms to synthesize dopamine in the brain: an in vitro study. Eur. J.
Pharmacol. 626, 171–178.
[12] Hiroi, T., Kishimoto, W., Chow, T., Imaoka, S., Igarashi, T. and Funae, Y. (2001)
Progesterone oxidation by cytochrome P450 2D isoforms in the brain.
Endocrinology 142, 3901–3908.
is the most efficient mammalian P450 enzyme to produce the crit-
ical morphine precursor.
In conclusion, new enzymatic activities were found for rat
CYP2D2 that have been incorrectly proposed for CYP2D1. A similar
correction of CYP2D1/CYP2D2 has previously been made for the
drugdebrisoquine [9,15]. These findingsbecomeparticularly impor-
tant for studies relying on results based on comparison of enzyme
activities between different rat strains [6,7,16–20]. Thus, the metab-
olism of some drugs, such as metoprolol, dextromethophan or 3,4-
methylenedioxymethamphetamine, might need further evaluation.
Acknowledgments
The authors would like to thank Dr. Leslie Hicks and Dr. Sophie
Alvarez, Donald Danforth Plant Science Center, for sequencing the
commercially available CYP2D1 and CYP2D2. We would like to
thank Megan Rolf for excellent technical assistance. This work
was supported by the National Institutes of Health Grant
#5R21DA024418 and the Mallinckrodt Foundation, St. Louis.
[13] Gerardy, R. and Zenk, M.H. (1993) Formation of salutaridine from (R)-
reticuline by a membrane-bound cytochrome P-450 enzyme from Papaver
somniferum. Phytochemistry 32, 79–86.
[14] Gesell, A., Rolf, M., Ziegler, J., Diaz Chavez, M.L., Huang, F.C. and Kutchan, T.M.
(2009) CYP719B1 is salutaridine synthase, the C–C phenol-coupling enzyme of
morphine biosynthesis in opium poppy. J. Biol. Chem. 284, 24432–24442.
[15] Schulz-Utermoehl, T., Bennett, A.J., Ellis, S.W., Tucker, G.T., Boobis, A.R. and
Edwards, R.J. (1999) Polymorphic debrisoquine 4-hydroxylase activity in the
rat is due to differences in CYP2D2 expression. Pharmacogenetics 9, 357–366.
[16] Barham, H.M., Lennard, M.S. and Tucker, G.T. (1994) An evaluation of
cytochrome P450 isoform activities in the female dark agouti (DA) rat:
relevance to its use as a model of the CYP2D6 poor metaboliser phenotype.
Biochem. Pharmacol. 47, 1295–1307.
[17] Ishmael, J.E., Franklin, P.H. and Murray, T.F. (1998) Dextrorotatory opioids
induce stereotyped behavior in Sprague–Dawley and Dark Agouti rats.
Psychopharmacology (Berl) 140, 206–216.
[18] Kerry, N.L., Somogyi, A.A., Mikus, G. and Bochner, F. (1993) Primary and
secondary oxidative metabolism of dextromethorphan. In vitro studies with
female Sprague–Dawley and Dark Agouti rat liver microsomes. Biochem.
Pharmacol. 45, 833–839.
[19] Malpass, A., White, J.M., Irvine, R.J., Somogyi, A.A. and Bochner, F. (1999) Acute
toxicity of 3,4-methylenedioxymethamphetamine (MDMA) in Sprague–
Dawley and Dark Agouti rats. Pharmacol. Biochem. Behav. 64, 29–34.
[20] Charron, G., Doudnikoff, E., Laux, A., Berthet, A., Porras, G., Canron, M.H.,
Barroso-Chinea, P., Li, Q., Qin, C., Nosten-Bertrand, M., Giros, B., Delalande, F.,
Van, D.A., Vital, A., Goumon, Y. and Bezard, E. (2011) Endogenous morphine-
like compound immunoreactivity increases in parkinsonism. Brain 134, 2321–
2338.
References
[1] Guengerich, F.P. (1995) Human cytochrome P450 enzymes in: Cytochrome
P450 (Ortiz deMontellano, P.R., Ed.), pp. 473–535, Plenum Press, New York.
[2] Evans, W.E. and Relling, M.V. (1999) Pharmacogenomics: translating
functional genomics into rational therapeutics. Science 286, 487–491.
[3] Eichelbaum, M. and Gross, A.S. (1990) The genetic polymorphism of
debrisoquine/sparteine metabolism–clinical aspects. Pharmacol. Ther. 46,
377–394.
[4] Sangar, M.C., Anandatheerthavarada, H.K., Tang, W., Prabu, S.K., Martin, M.V.,
Dostalek, M., Guengerich, F.P. and Avadhani, N.G. (2009) Human liver
mitochondrial cytochrome P450 2D6–individual variations and implications
in drug metabolism. FEBS J. 276, 3440–3453.
[5] Matsunaga, E., Zanger, U.M., Hardwick, J.P., Gelboin, H.V., Meyer, U.A. and
Gonzalez, F.J. (1989) The CYP2D gene subfamily: analysis of the molecular
basis of the debrisoquine 4-hydroxylase deficiency in DA rats. Biochemistry
28, 7349–7355.
[6] Mikus, G., Somogyi, A.A., Bochner, F. and Eichelbaum, M. (1991) Thebaine O-
demethylation to oripavine: genetic differences between two rat strains.
Xenobiotica 21, 1501–1509.